{"filing":{"accession_number":"0001082554-26-000028","cik":"0001082554","ticker":"UTHR","company_name":"UNITED THERAPEUTICS Corp","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"uthr-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255426000028/uthr-20260805.htm"},"events":[{"id":24369,"run_id":22072,"accession_number":"0001082554-26-000028","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"United Therapeutics issued a press release on August 5, 2026, disclosing its financial results for the quarter ended June 30, 2026, including total revenues of $783.3 million, net income of $333.0 million, and detailed breakdowns of product revenues and operating expenses. This is a standard quarterly earnings release filed under Item 2.02 with the full press release attached as Exhibit 99.1.","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24888,"accession_number":"0001082554-26-000028","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"United Therapeutics issued a press release on August 5, 2026, disclosing its financial results for the quarter ended June 30, 2026, including total revenues of $783.3 million, net income of $333.0 million, and detailed breakdowns of product revenues and operating expenses. This is a standard quarterly earnings release filed under Item 2.02 with the full press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:25:51.851389+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24888,"accession_number":"0001082554-26-000028","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"United Therapeutics issued a press release on August 5, 2026, disclosing its financial results for the quarter ended June 30, 2026, including total revenues of $783.3 million, net income of $333.0 million, and detailed breakdowns of product revenues and operating expenses. This is a standard quarterly earnings release filed under Item 2.02 with the full press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:25:51.851389+00:00","company_name":"UNITED THERAPEUTICS Corp","ticker":"UTHR","filing_date":"2026-08-05"}]}